When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma

Area of Science:

• Oncology
• Cancer Research
• Pharmacology

Background:

• Soft tissue sarcomas (STS) are rare adult cancers with poor prognosis in the metastatic setting.
• Current standard treatment with chemotherapy has limited efficacy.
• Emerging therapies like molecular targeted agents (MTAs) and immunotherapies are under investigation.

Purpose of the Study:

• To review recent advances in STS treatment focusing on MTAs and immunotherapy.
• To explore strategies for overcoming treatment resistance and the outcomes of combination therapies.
• To highlight the role of molecular profiling in guiding personalized treatment strategies.

Main Methods:

• Review of current literature on MTAs and immunotherapies in STS.
• Analysis of clinical trial data and research findings.
• Discussion of emerging treatment modalities and biomarkers.

Main Results:

• MTAs, including antiangiogenic agents and NTRK inhibitors, have shown success in specific STS subtypes.
• Single-agent immunotherapy has not yet revolutionized STS treatment.
• Combination strategies involving MTAs and immunotherapies show promising preliminary results.

Conclusions:

• Understanding the tumor microenvironment and MTA immunogenicity is crucial for developing effective treatments.
• Transcriptomic profiling can aid in patient selection and treatment assignment.
• Personalized treatment strategies combining MTAs and immunotherapies, guided by biomarkers, represent the future of advanced STS care.